137 related articles for article (PubMed ID: 37773987)
1. Evaluation of Predict, a prognostic risk tool, after diagnosis of a second breast cancer.
Deng Z; Jones MR; Wolff AC; Visvanathan K
JNCI Cancer Spectr; 2023 Oct; 7(6):. PubMed ID: 37773987
[TBL] [Abstract][Full Text] [Related]
2. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States.
Iqbal J; Ginsburg O; Rochon PA; Sun P; Narod SA
JAMA; 2015 Jan; 313(2):165-73. PubMed ID: 25585328
[TBL] [Abstract][Full Text] [Related]
3. Second primary breast cancer occurrence according to hormone receptor status.
Kurian AW; McClure LA; John EM; Horn-Ross PL; Ford JM; Clarke CA
J Natl Cancer Inst; 2009 Aug; 101(15):1058-65. PubMed ID: 19590058
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.
Engelhardt EG; van den Broek AJ; Linn SC; Wishart GC; Rutgers EJT; van de Velde AO; Smit VTHBM; Voogd AC; Siesling S; Brinkhuis M; Seynaeve C; Westenend PJ; Stiggelbout AM; Tollenaar RAEM; van Leeuwen FE; van 't Veer LJ; Ravdin PM; Pharaoh PDP; Schmidt MK
Eur J Cancer; 2017 Jun; 78():37-44. PubMed ID: 28412587
[TBL] [Abstract][Full Text] [Related]
5. Validation of the PREDICT Prognostication Tool in US Patients With Breast Cancer.
Stabellini N; Cao L; Towe CW; Miller ME; Sousa-Santos AH; Amin AL; Montero AJ
J Natl Compr Canc Netw; 2023 Oct; 21(10):1011-1019.e6. PubMed ID: 37856198
[TBL] [Abstract][Full Text] [Related]
6. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
[TBL] [Abstract][Full Text] [Related]
7. External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer.
Wang Y; Broeks A; Giardiello D; Hauptmann M; Jóźwiak K; Koop EA; Opdam M; Siesling S; Sonke GS; Stathonikos N; Ter Hoeve ND; van der Wall E; van Deurzen CHM; van Diest PJ; Voogd AC; Vreuls W; Linn SC; Dackus GMHE; Schmidt MK
Eur J Cancer; 2023 Dec; 195():113401. PubMed ID: 37925965
[TBL] [Abstract][Full Text] [Related]
8. Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women.
Hoskins KF; Danciu OC; Ko NY; Calip GS
JAMA Oncol; 2021 Mar; 7(3):370-378. PubMed ID: 33475714
[TBL] [Abstract][Full Text] [Related]
9. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
10. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
Bauer KR; Brown M; Cress RD; Parise CA; Caggiano V
Cancer; 2007 May; 109(9):1721-8. PubMed ID: 17387718
[TBL] [Abstract][Full Text] [Related]
11. Variation in second breast cancer risk after primary invasive cancer by time since primary cancer diagnosis and estrogen receptor status.
Lowry KP; Ichikawa L; Hubbard RA; Buist DSM; Bowles EJA; Henderson LM; Kerlikowske K; Specht JM; Sprague BL; Wernli KJ; Lee JM
Cancer; 2023 Apr; 129(8):1173-1182. PubMed ID: 36789739
[TBL] [Abstract][Full Text] [Related]
12. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.
Dunnwald LK; Rossing MA; Li CI
Breast Cancer Res; 2007; 9(1):R6. PubMed ID: 17239243
[TBL] [Abstract][Full Text] [Related]
13. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA;
J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216
[TBL] [Abstract][Full Text] [Related]
14. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer.
Wishart GC; Azzato EM; Greenberg DC; Rashbass J; Kearins O; Lawrence G; Caldas C; Pharoah PD
Breast Cancer Res; 2010; 12(1):R1. PubMed ID: 20053270
[TBL] [Abstract][Full Text] [Related]
15. Validation of the online PREDICT tool in a cohort of early breast cancer in Brazil.
Magário MB; Santos RRD; Teixeira LA; Tiezzi DG; Pimentel FF; Carrara HHA; Andrade JM; Reis FJCD
Braz J Med Biol Res; 2022; 55():e12109. PubMed ID: 36350970
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of the prognostic model PREDICT using the POSH cohort of women aged ⩽40 years at breast cancer diagnosis.
Maishman T; Copson E; Stanton L; Gerty S; Dicks E; Durcan L; Wishart GC; Pharoah P; ; Eccles D
Br J Cancer; 2015 Mar; 112(6):983-91. PubMed ID: 25675148
[TBL] [Abstract][Full Text] [Related]
17. Racial and ethnic disparities in treatment-related heart disease mortality among US breast cancer survivors.
Vo JB; Ramin C; Lawrence WR; Barac A; Ho KL; Rhee J; Veiga LHS; Berrington de González A
JNCI Cancer Spectr; 2023 Mar; 7(2):. PubMed ID: 36943362
[TBL] [Abstract][Full Text] [Related]
18. Development of a prediction model for breast cancer based on the national cancer registry in Taiwan.
Huang CC; Chan SY; Lee WC; Chiang CJ; Lu TP; Cheng SH
Breast Cancer Res; 2019 Aug; 21(1):92. PubMed ID: 31409418
[TBL] [Abstract][Full Text] [Related]
19. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2017 Sep; 165(2):391-402. PubMed ID: 28601929
[TBL] [Abstract][Full Text] [Related]
20. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.
Narod SA; Iqbal J; Giannakeas V; Sopik V; Sun P
JAMA Oncol; 2015 Oct; 1(7):888-96. PubMed ID: 26291673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
